Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies by Mantia-Smaldone, Gina M et al.
© 2011  Mantia-Smaldone et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2011:3 25–38
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
25
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/CMR.S8759
Targeted treatment of recurrent platinum-resistant 
ovarian cancer: current and emerging therapies
Gina M Mantia-Smaldone1
Robert P edwards2
Anda M vlad3
1Division of Gynecologic Oncology, 
Hospital of the University of 
Pennsylvania, Philadelphia, PA, 
USA; 2Division of Gynecologic 
Oncology, Magee-womens Hospital 
of the University of Pittsburgh 
Medical Center, Pittsburgh, PA, 
USA; 3Department of Obstetrics, 
Gynecology and Reproductive 
Sciences, University of Pittsburgh 
School of Medicine and  
Magee-womens Research  
institute, Pittsburgh PA, USA
Correspondence: Gina M Mantia-Smaldone 
Division of Gynecologic Oncology, 
Hospital of the University of Pennsylvania, 
3rd floor, PCAM, 34th and Spruce  
Streets, Philadelphia, PA 19104, USA 
Tel +1 215-662-3327 
Fax +1 215-573-5408 
email gina.mantia@uphs.upenn.edu
Abstract: With advances in surgical techniques and chemotherapeutic agents, mortality rates 
from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, 
EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. 
Prognosis is especially disappointing for women with platinum-resistant disease, where 80% 
of patients will fail to respond to available therapies. Emerging treatment strategies have sub-
sequently focused on targets which are integral to tumor growth and metastasis. In this review, 
we will focus on those innovative agents currently under investigation in clinical trials.
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Introduction
With almost 14,000 deaths expected in 2010, epithelial ovarian cancer (EOC) remains 
the most lethal gynecologic malignancy.1 Approximately 75% of women with EOC 
present with advanced stage disease (stage III or IV).2 Current management of ovar-
ian cancer at initial presentation typically consists of surgical cytoreduction followed 
by platinum/taxane combination chemotherapy. While 70% to 80% of patients with 
advanced EOC will initially respond to this traditional therapy, more than 60% will 
experience a recurrence of disease and 70% to 90% will ultimately die of their disease.2 
Predictors for recurrence include late stage, residual disease, advanced age, histologic 
grade, poor performance status, clear cell or mucinous histology, and suboptimal 
normalization of CA125 levels following first-line therapy.3,4
Patients with recurrent EOC are characterized by their initial response to platinum-
based therapy.5 Women who experience recurrences greater than 6 months following 
a response to platinum-based therapy (ie, platinum-free interval [PFI] .6 months) are 
characterized as having platinum-sensitive disease.6 Patients in this category are likely 
to respond to a platinum-based therapy at the time of relapse and are generally offered 
a platinum agent or a platinum-containing doublet.7 Carboplatin-based combination 
therapy, especially carboplatin with paclitaxel, is most commonly administered as 
the first-line therapy for recurrence.8 Alternatively, carboplatin combined with gem-
citabine or pegylated liposomal doxorubicin can be used, giving similar response and 
survival rates.9,10
Women who experience recurrences within 6 months following an initial response 
to platinum-based therapy (ie, PFI , 6 months) or who experience stable disease during 
platinum-based therapy are characterized as having platinum-resistant ovarian   cancer.6 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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This group will often also encompass those individuals who 
experience disease progression during platinum-based therapy 
(ie, platinum-refractory).11 With platinum-resistant disease, 
the selection of treatment is often made on an individual basis, 
as treatment for recurrent disease is generally not curable.12 
Goals of treatment often include controlling the disease-
related symptoms, limiting treatment-related toxicity, and 
optimizing quality of life.13 Patients with platinum-resistant 
tumors are typically treated with a single cytotoxic agent that 
is not cross-resistant with platinum compounds; these options 
will be briefly discussed below.7
Current reports indicate a 20% response rate with contem-
porary agents,6 emphasizing an absolute need for the develop-
ment of innovative and effective therapeutic strategies for the 
management of advanced EOC. In this review we will briefly 
discuss the traditional chemotherapeutic options for recurrent, 
platinum-resistant epithelial ovarian cancer and then focus 
on novel therapeutic strategies currently under investigation. 
A MEDLINE search combining the following medical subject 
terms: “recurrent ovarian cancer, platinum resistant disease 
and treatment”, was performed from 2000 to 2010 in order to 
identify novel targets for recurrent, platinum-resistant   ovarian 
cancer; only articles written in the English language were 
included in this review. Ongoing and enrolling clinical trials 
involving emerging therapeutic agents were subsequently 
identified by searching the ClinicalTrials.gov registry, abstracts 
of scientific meetings, and reference lists of included studies. 
A summary of current clinical trials is presented in Table 1. 
While the results of many clinical trials are not yet available, 
we discuss how novel targeted therapies may play a future role 
in the management of this deadly disease.
Chemotherapy resistance assays
Chemosensitivity and resistance assays, which utilize 
molecular and cellular strategies with individual tumor 
biopsies, aim to customize therapy for women with ovarian 
Table 1 Current clinical trials involving targeted agents in platinum-resistant epithelial ovarian cancer
Process  Molecular  
target
Agent Trial  
phase
Additional agents ClinicalTrials.gov   
identifier 
Anti-tumor immunity MUC1 MUC1-KLH vaccine  i Adjuvant QS21 NCT00006041
Anti-tumor immunity whole  
tumor cell
Dendritic cells ii Ontak NCT00703105
1 Bevacizumab/cyclophosphamide NCT00683241
0 Daclizumab/bevacizumab NCT01132014
Anti-tumor immunity whole  
tumor cell
Adoptive transfer  
of T lymphocytes
i/ii tumor lysate-pulsed  
dendritic cells
NCT00603460 
Angiogenesis veGF Bevacizumab iii Paclitaxel/topotecan/PLD NCT00976911
ii Gemcitabine NCT01131039
ii PLD NCT00846612
ii PLD NCT00945139
ii Abraxane NCT00407563
Angiogenesis veGFR-2 Ramucirumab ii N/A NCT00721162
Angiogenesis veGF Aflibercept  
(veGF Trap)
i/ii Docetaxel NCT00436501
Angiogenesis veGFR2 Cediranib iii Carboplatin/paclitaxel NCT00544973
Angiogenesis  
Cellular proliferation
veGFR2  vandetanib i/ii PLD NCT00862836
eGFR ii Docetaxel NCT 00872989
Angiogenesis  
Cellular proliferation
eGFR Panitumumab ii PLD NCT00861120
Angiogenesis  
Cellular proliferation
eGFR erlotinib ii Topotecan NCT01003938
ii Bevacizumab NCT00126542
ii Bevacizumab NCT00696670
Angiogenesis veGFR
PDGFR
C-Kit
Sorafenib ii
ii
Topotecan
Gemcitabine
NCT01047891
NCT00096395
Angiogenesis PDGFRα iMC3G3 ii PLD NCT00913835
Folate metabolism FRα MORAb-003 ii Paclitaxel NCT00738699
DNA repair PARP veliparib i PLD NCT01145430 
DNA repair PARP iniparib ii Gemcitabine NCT01033292 
Abbreviations: MUC1, mucin 1; veGF, vascular endothelial growth factor; PLD, pegylated liposomal doxorubicin; veGFR-2, vascular endothelial growth factor receptor 2; 
N/A, not applicable; eGFR, epidermal growth factor receptor; PDGFRα, platelet derived endothelial growth factor receptor alpha; FRα, folate receptor alpha; PARP,   
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cancer, especially those with recurrent disease. The utility of 
a chemosensitivity assay in recurrent disease was examined 
in a prospective randomized control trial of 180 women 
with platinum-resistant disease.14 Response rates (40.5% 
vs 31.5%) and median progression-free survival (104 vs 
93 days) were greater in women randomized to the sensi-
tivity assay-directed group compared with the physician’s 
choice arm. While overall survival was similar between 
groups, the authors suggest that chemosensitivity testing 
may provide useful information in select patients. Several 
national organizations, including the American Society of 
Clinical   Oncology, have released statements to help direct 
clinical use of these assays; at this time, there are not enough 
reliable data to recommend the use of these assays in clini-
cal practice.15 Future studies focusing on the utility and cost 
benefits of these assays in platinum-resistant disease may 
help to clarify their impact on patients’ outcomes.
Chemotherapy use  
in platinum-resistant disease
Nonplatinum-based single-agent chemotherapy is considered 
first-line therapy in the treatment of recurrent, platinum-
resistant EOC. Commonly utilized agents include pegylated 
liposomal doxorubicin, paclitaxel, gemcitabine, topotecan, 
docetaxel, and etoposide, with response rates ranging from 
10% to 30%.6 Often the choice of agent is driven by its side 
effect profile, administration, and availability.
Pegylated liposomal doxorubicin (PLD), a DNA 
intercalating agent with reported objective response rates 
(ORRs) as high as 26%, is commonly administered as the 
first-choice nonplatinum reagent for recurrent platinum-
resistant disease.16,17 Due to its adverse events, the most 
significant of which is palmar-plantar erythrodysesthesia 
(hand–foot syndrome), PLD is currently being evaluated as 
a component of combination therapy.18
Paclitaxel, a microtubule inhibitor, has produced ORRs 
up to 30% in women with platinum-resistant EOC,5 and com-
bination paclitaxel and carboplatin therapy has also demon-
strated objective clinical benefits.19 Common adverse events 
with paclitaxel include neurotoxicity and myelosuppression, 
events that can be potentially improved with different dos-
ing schedules. Through a similar mechanism, docetaxel has 
demonstrated activity in cases of platinum-resistant disease 
but with reduced efficacy and increased patient toxicity.20
Single-agent gemcitabine, a nucleoside pyrimidine 
analog, has a reported ORR of 16% in platinum- and 
paclitaxel-refractory disease.21 While myelosuppression is 
a common dose-limiting toxicity, gemcitabine may be an 
acceptable alternative to PLD given similar response rates 
and   progression-free survival in a recent phase III study.22
Topoisomerase inhibitors utilized in platinum-resistant 
patients include topotecan and etoposide. While respective 
response rates of 12% to 14%23 and 26.8%24 with topotecan 
have been reported, dosing is limited by hematotoxicity. 
In a phase II Gynecologic Oncology Group (GOG) study, 
Rose et al reported a response rate of 32% with etoposide in 
platinum and paclitaxel resistant patients.25
Second-line agents for platinum-resistant disease 
include irinotecan, vinorelbine, ifosfamide, and leucovorin-
  modulated 5-fluorouracil. In a single-institution phase II trial, 
  irinotecan, a topoisomerase inhibitor, produced a response 
rate of 17.2% in 31 patients with platinum-resistant/  refractory 
EOC or primary peritoneal cancer (PPC) with acceptable 
toxicity.26 Vinorelbine, an antimicrotubule agent, has dem-
onstrated a response rate of 21% in a recent phase II trial.27 
Ifosfamide, an alkylating agent, produced a response rate of 
12% in a phase II trial of 41 patients with platinum-resistant 
disease, the most common reported toxicities including 
myelosuppression, nephrotoxicity, and central nervous dys-
function.28 5-Fluorouracil, a pyrimidine analog, although well 
tolerated, produced a response rate of only 18% in a recent 
retrospective report.29
Novel cytotoxic therapies
Emerging cytotoxic agents are currently being introduced into 
the management of platinum-resistant ovarian cancer. These 
include chemotherapeutic compounds classified in drug 
categories with known activity in EOC, including taxanes 
(eg, paclitaxel poliglumex), anthracyclines (eg, sabarubicin), 
alkylating agents (eg, canfosfamide), and topoisomerase 
inhibitors (eg, rubitecan), or novel drug categories, such as 
epothilones (eg, ixabepilone, patupilone).
Ixabepilone belongs to a new class of agents, epothilones, 
which act to stabilize microtubules. While mechanistically 
similar to taxanes, epothilones are structurally unrelated 
and may circumvent mechanisms in taxane resistance.30 
In a phase II GOG trial, ixabepilone produced an ORR of 
14.3% in 49 women with platinum- and taxane-resistant 
EOC or PPC.31 Clinical trials with ixabepilone monotherapy 
(NCT00025155, NCT00030706) and combination therapy 
with pegylated liposomal doxorubicin (NCT00182767) are 
currently accruing.
Trabectedin is an anti-tumor agent which binds to DNA 
and interferes with DNA repair, thereby blocking cell cycle 
progression.32 In a multicenter phase II trial, trabectedin 
monotherapy was active in platinum-resistant EOC with Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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an ORR of 6.3%.33 Trabectedin in combination with PLD 
was recently evaluated in a randomized phase III trial with 
platinum-sensitive and -resistant recurrent disease.18 While 
the response rate was significantly higher in women with 
platinum-sensitive disease receiving combination therapy 
vs PLD monotherapy (35.3% vs 22.6%, P = 0.004), ORRs 
were not statistically different between treatment arms in the 
platinum-resistant population.
Pemetrexed is a folate antimetabolite which inhibits 
a number of enzymes critical to nucleotide synthesis.34 
In a phase II GOG trial, pemetrexed monotherapy was 
administered to 48 women with platinum-resistant EOC or 
PPC, reporting an ORR of 21% with median progression-
free and overall survivals of 2.9 months and 11.4 months, 
respectively.35
Phenoxodiol promotes Fas-mediated apoptosis by activat-
ing the mitochondrial caspase system, inhibiting the X-linked 
inhibitor of apoptosis and disrupting FLICE inhibitory 
protein (FLIP) expression.36 In vitro and preclinical animal 
studies indicate that phenoxodiol can sensitize EOC cells to 
carboplatin, paclitaxel, and gemcitabine,37 and phenoxodiol 
combination therapies including carboplatin, paclitaxel, and 
docetaxel are currently being evaluated.
Third-generation platinum agents, including oxaliplatin, 
satraplatin, and picoplatin, have incomplete cross-resistance 
with either cisplatin or carboplatin and have subsequently 
been shown to have minor activity in platinum-resistant 
disease. In a phase II GOG trial, single-agent oxaliplatin 
produced an ORR of 4.3% in 23 women with platinum-
resistant or -refractory EOC,38 which has led to investigation 
of oxaliplatin in combination with 5-fluoruracil/leucovorin,39 
paclitaxel, 40 PLD,41 and gemcitabine.42 Satraplatin is an orally 
administered platinum agent with in vitro activity against 
platinum-resistant ovarian cancer cell lines;43 however, 
these findings have not yet been confirmed in clinical trials. 
Picoplatin is currently under investigation in a phase I trial 
of patients with advanced solid tumors, including ovarian 
cancer (NCT00465725).
Emerging approaches  
to platinum-resistant EOC
In addition to novel cytotoxic agents, targeted molecular 
strategies have been employed in the treatment of recurrent, 
platinum-resistant ovarian cancer. These strategies attempt 
to manipulate processes critical to ovarian carcinogenesis, 
including cellular growth and proliferation, cellular adhesion, 
intracellular signaling pathways, angiogenesis, and DNA 
repair pathways.44 In the following section, we will focus 
on emerging agents targeting host-tumor immune responses, 
intracellular signaling pathways, cellular adhesion molecules, 
endocrine pathways, and DNA repair mechanisms.
Immunotherapy
Effective host anti-tumor immune responses have the 
potential to influence prognosis in patients with EOC. The 
presence of tumor-infiltrating lymphocytes (TILs) has been 
correlated with significantly improved progression-free and 
overall survival rates in women with advanced stage EOC.45 
Further, the presence of CD4+CD25+FOXP3+ T   regulatory 
(Treg) cells in tumors has a reported negative impact on 
survival, suggesting that these cells might suppress host 
anti-tumor immunity.46,47 Thus, by manipulating the host 
immune system, it may be possible to enhance host anti-
tumor immune responses and improve patient outcomes, 
especially in those with platinum-resistant disease. Current 
immunotherapeutic approaches employ either vaccines based 
on tumor-associated antigens (TAA), antitumor cytokines, 
or antibodies targeting co-stimulatory and immunosuppres-
sive molecules.48
Tumor antigens
Several proteins that are abnormally expressed in cancer 
cells, due to mutations, overexpression, or post-translational 
modifications, have been identified and are currently studied 
as targets for immunotherapy. In a recent analysis from the 
National Cancer Institute Pilot Project for the acceleration of 
translational research, 75 tumor antigens were priority ranked 
for cancer vaccine development.49 Some of these antigens, 
including MUC1, CA125, human epidermal growth factor 
receptor 2 (HER2)/neu, membrane folate receptor, TAG-72, 
mesothelin, and NY-ESO-1, are targets of therapeutic tumor 
vaccines in ovarian cancer.48
Due to its oncogenic properties, immunogenicity and 
expression pattern, MUC1 received the second highest 
priority ranking, after WT1.49 MUC1 is a transmembrane 
mucin overexpressed in more than 90% of epithelial ovar-
ian cancers, including platinum-resistant tumors.50,51 Thus, 
MUC1 has been often studied as a target for antibody-based 
immunotherapy. A phase I trial using a murine anti-MUC1 
antibody (HMFG1) was conducted in 26 patients with 
  persistent/recurrent ovarian cancer following platinum-based 
chemotherapy.51 While no clinical responses were appreci-
ated, anti-HMFG1 and anti-MUC1 antibody responses were 
significantly elevated in those individuals completing the 
vaccination regimen. In a phase I/II trial, 52 women received 
intraperitoneal (IP) injections of a radioactively-labeled Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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form of this antibody,   yttrium-90-muHMFG1,   following 
traditional surgery and platinum-based   chemotherapy 
with improved median survival rates compared with 
historical controls.50 While a subsequent phase III trial 
failed to show a survival benefit with IP administration 
of yttrium-90-muHMFG1 as consolidation treatment, the 
authors reported a significant decrease in IP recurrences 
in the treatment group.52   Unfortunately, this finding was 
offset by increased extraperitoneal recurrences. In addition 
to MUC1-specific antibodies, vaccines based on MUC1 
  peptides designed to trigger T cell immunity have been 
proposed in ovarian cancer (NCT00006041).
CA125 (MUC16), another member of the mucin family, 
is a marker utilized to monitor response to chemotherapy 
and to survey for disease recurrence. Approximately 80% 
of ovarian cancer tumors are CA125 positive, suggesting 
that immunotherapy targeting this TAA may be of clini-
cal relevance.53 Monoclonal antibodies to CA125 (B43.13, 
oregovomab) have been utilized in phase II and III trials of 
patients with recurrent disease.53,54 In the first trial, oregov-
omab was administered to 13 heavily pretreated, recurrent 
ovarian cancer patients, including 6 women with platinum-
resistant disease.53 Oregovomab and CA125 antibody and T 
cell specific responses were reported in greater than 50% of 
the patients. While there were no objective responses, 23% 
of patients experienced stabilization of disease and survival 
greater than 2 years, and these clinical responses corre-
sponded with robust immune responses to treatment.53 In the 
latter trial, 20 patients with advanced recurrent ovarian cancer 
(and with a history of platinum exposure) received orego-
vomab followed by optional chemotherapy.54   Anti-CA125 
antibodies were produced in 2 (11%) patients, while 15 
(79%) of patients developed human anti-mouse antibodies 
(HAMAs) and anti-oregovomab antibodies. Overall median 
survival and progression-free survival was 70.4 weeks (4.6 
to 14.6 weeks) and 11 weeks (2.6 to 114.6 weeks), respec-
tively. T cell responses specific to CA125 and/or autologous 
tumor were significantly associated with improved survival 
(P = 0.002).
Anti-idiotypic antibodies to CA125 (ACA125, abagov-
omab) have also been utilized in clinical trials.55,56 Generated 
against primary anti-CA125 antibodies, these antibodies can 
serve as surrogate antigens given that they imitate the antigen 
of interest, and it has been postulated that vaccination with 
anti-idiotypic antibodies can increase host responses.48 In a 
phase I/II trial, abagovomab was administered to 119 patients 
with advanced ovarian cancer, including 44 patients with plat-
inum-resistant disease.56 Antibodies to ACA125 and CA125 
were generated in 68% and 50% of patients, respectively, 
and antibody-dependent cell-mediated cytotoxicity (ADCC) 
of CA125-positive cancer cells was demonstrated in 27% 
of patients. Individuals with anti-ACA125 antibodies had a 
significantly longer survival compared to those without such 
a response (median, 23.4 months vs 4.9 months; P , 0.0001). 
Two additional studies demonstrated the presence of anti-
abagovomab antibodies in all evaluable patients, but these 
responses were not assessed for association with survival 
benefit due to study design.55,57
Cytokine therapy
Proinflammatory cytokines, including interleukins (IL) 2, 
4, 7, 12 and 18, interferon gamma (IFN-γ), tumor necro-
sis factor alpha (TNF-α), and granulocyte-macrophase 
colony-stimulating factor (GM-CSF), have been utilized in 
preclinical models to induce anti-tumor immune   responses.58 
In a phase II trial in patients with platinum-resistant and 
refractory EOC, IP IL-2 therapy resulted in an overall 
response rate of 25% with a median survival time of 2.1 
years.59 The authors also reported a significant association 
between patient survival and changes in CD3 T cells and 
IFN-γ producing CD8 T cell counts at early treatment time 
points, suggesting that anti-tumor responses may be critical 
to prognosis.
GM-CSF alone and in combination with recombinant 
IFN-γ 1b (rIFN-γ 1b) has recently been incorporated into 
phase II trials.60,61 Roche et al used single agent GM-CSF 
in 72 women with asymptomatic recurrent müllerian 
malignancy without an indication for immediate systemic 
chemotherapy.60 While 1 patient experienced a complete 
response and 20 patients experienced stable disease follow-
ing treatment, 70% of women experienced a drop in CA125 
levels from baseline. GM-CSF in combination with rIFN-γ 1b 
and carboplatin produced a response rate of 56% in a cohort 
of 59 patients with recurrent, platinum-sensitive ovarian, 
fallopian tube and PPC.61 Given these encouraging results, 
further studies examining efficacy in platinum-resistant 
disease are necessary.
IFN-γ induced upregulation of major histocompatibility 
complex molecular expression on antigen presenting cells, 
including dendritic cells, macrophages and B cells, can 
enhance host immune responses via activation of T cell-
  mediated pathways.62 Preclinical evaluation of a CD80 (B7-1)/
IFN-γ modified vaccine showed enhancement of tumor-
specific cytotoxic activity, resulting in reduction of tumor 
growth.63 However, this vaccine has not yet been attempted 
in clinical trials with platinum-resistant disease.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Other immune strategies
In addition to TAA and recombinant cytokine therapies men-
tioned above, vaccine-approaches in EOC have also utilized 
whole tumor cell lysates and dendritic cells in an attempt to 
boost host anti-tumor immune responses. The former affords 
the opportunity for broad tumor antigen exposure, while 
use of dendritic cells (DCs) enhances anti-tumor immunity 
via specific tumor-antigen presentation and activation of 
effector T cells.44 The first and currently only Food and 
Drug Administration approved cancer therapeutic vaccine 
is the DC-based Provenge®   vaccine (  Dendreon Corporation, 
Seattle, WA) administered as autologous cellular therapy in 
castrate-resistant prostate cancer.64 The value of Provenge 
in triggering effective immunity against other cancer types, 
including ovarian cancer, remains to be established.
DC-based immunotherapy in ovarian cancer has focused 
on several approaches, including exposure (also known as 
pulsing) of DCs to whole cell tumor lysates, defined ovarian 
tumor peptides, and ovarian tumor cells, to induce a cytotoxic 
T lymphocyte (CTL) response.65 In a pilot study, autologous 
DCs were pulsed with HER-2/neu or MUC1-derived peptides 
and administered to 10 patients with advanced breast or ovar-
ian cancer.66 Half of the patients experienced peptide-specific 
CTL responses, but unfortunately these responses were 
not correlated with long-term outcomes. In a phase I trial, 
autologous tumor antigen-pulsed DCs were administered 
to 6 patients with progressive or recurrent ovarian cancer.67 
Half of the patients experienced stabilization of disease with 
progression-free intervals of 8 to 45 months, and lymphopro-
liferative responses were reported in 2 patients. Given these 
promising data, DC-based immunotherapy is currently the 
focus of several new trials (NCT00703105, NCT00683241, 
and NCT01132014) which will hopefully demonstrate an 
impact on long-term prognosis.
Adoptive immunity is a process by which immune cells, 
including T lymphocytes, B lymphocytes, natural killer 
cells, and macrophages, are removed from an individual, 
modified extracorporeally and then placed back into the same 
individual.68 The adoptive transfer of autologous TILs has 
proven to be quite effective in metastatic melanoma patients, 
with reported ORRs of greater than 50%.69 The same process 
was met with high response rates in a sample of women with 
advanced or recurrent EOC,70 and subsequent studies in ovar-
ian cancer have examined the utility of adoptive transfer with 
modified T cells to enhance antitumor activity.71,72 A phase 
I/II trial has been proposed in which patients with recurrent 
EOC or PPC will undergo adoptive transfer of ex vivo CD3/
CD28-costimulated autologous peripheral blood T cells 
along with tumor lysate-pulsed DCs (DCVax®-L; Northwest 
  Biotherapeutics, Inc., Bethesda, MD) (NCT00603460) in 
order to determine the feasibility and safety of this combina-
tion and progression-free survival at 6 months.
In addition, investigations have begun focusing on mol-
ecules (eg, cytotoxic T lymphocyte-associated antigen 4, 
CTLA-4)73 and cell populations (Tregs)74 which suppress 
host immune responses. These trials will hopefully reinforce 
the utility of these novel immunotherapeutic techniques in 
the treatment of recurrent EOC and lay the foundation for 
studies specific to platinum-resistant disease.
Tyrosine kinase receptors and 
intracellular signaling pathways
Angiogenesis is critical to tumor growth/metastasis and 
several proangiogenic factors, including vascular endothelial 
growth factor (VEGF), IL-8, platelet-derived endothelial cell 
growth factor (PDGF), angiogenin, and fibroblast growth 
factor (FGF), have been implicated in tumorigenesis.75 
Molecules, including VEGF, epidermal growth factor recep-
tor (EGFR), and PDGF among numerous others, play critical 
roles in processes that support cancer growth and metastasis, 
and several tyrosine kinase receptors and intracellular 
signaling pathways are currently under review for ovarian 
cancer targeted therapy. Of these molecules, VEGF has been 
the most commonly studied, given that it is abundantly pres-
ent in the serum of patients with EOC,76,77 and that elevated 
VEGF levels have been associated with poor survival.78
Bevacizumab is a humanized monoclonal antibody 
which interferes with the binding of VEGF-A to its receptor. 
Bevacizumab has been utilized as monotherapy or in combi-
nation in several clinical trials, where its efficacy and safety 
have been demonstrated.79,80 GOG-170D was a phase II 
trial in which single-agent bevacizumab was administered 
intravenously to 62 women with persistent or recurrent 
EOC or PPC (41.9% with platinum-resistant disease) to 
assess efficacy and tolerability.79 Clinical responses were 
observed in 21% of patients, and median progression-free 
and overall survivals were 4.7 and 17 months, respectively. 
Bevacizumab was well tolerated in this sample, suggesting 
it may serve as an effective second- or third-line option for 
patients with EOC/PPC.
Cannistra et al investigated the use of bevacizumab mono-
therapy in a sample of 44 women with platinum-resistant 
EOC or PPC who had experienced disease progression during 
or within 3 months of discontinuing topotecan or liposomal 
doxorubicin.80 Seven patients (15.9%) experienced par-
tial responses; median progression-free and overall survival Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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were 4.4 and 10.7 months, respectively, at study conclusion. 
However, enrollment was closed early in this study due to a 
higher than expected rate of gastrointestinal perforation (GIP, 
11.4%). GIP was significantly associated with increased 
number of prior chemotherapy regimens, suggesting this 
adverse event may be due to the advanced disease status in 
this patient sample. This study suggests that bevacizumab 
monotherapy may play a role in the treatment of patients with 
heavily pretreated, platinum-resistant EOC although further 
prospective evaluation is warranted.
Bevacizumab in combination with taxanes and cyclo-
phosphamide has also been investigated in women with 
recurrent EOC.81,82 In a phase II trial evaluating bevaci-
zumab and cyclophosphamide therapy in 70 patients, 24% 
of patients experienced a partial response to therapy and 
median   progression-free and overall survival were 7.2 and 
16.9 months respectively.82 The results of a recently completed 
phase II trial of weekly topotecan with bevacizumab in women 
with platinum-resistant EOC, fallopian tube cancer, or PPC 
(NCT00343044) are also currently pending. Other bevaci-
zumab combination regimens including paclitaxel, topotecan, 
or liposomal doxorubicin (NCT00976911, NCT01131039, 
NCT00846612, NCT00945139, NCT00407563) are cur-
rently in the evaluation process. The results of these trials will 
certainly generate considerable interest and may potentially 
impact treatment for recurrent, platinum-resistant disease.
Ramucirumab (IMC-1121B), which blocks VEGFR-2 
on tumor endothelial cells, is another human monoclonal 
antibody targeting the VEGF pathway.83 The safety and tol-
erability of this antibody have been demonstrated by a near-
completed phase I trial,83 while a nonrandomized phase II trial 
(NCT00721162) is investigating ramucirumab monotherapy 
in platinum-refractory persistent or recurrent EOC, PPC, or 
fallopian tube cancer to assess efficacy.84
VEGF Trap (aflibercept) is a recombinant fusion protein 
which combines the VEGF binding domains of VEGFR1 and 
VEGFR2 with the Fc region of immunoglobulin (IgG1) and 
acts as a soluble decoy receptor by binding to VEGF.85 In 
a randomized phase II trial, 11% of patients with recurrent, 
platinum-resistant disease achieved objective responses with 
VEGF Trap,86 and VEGF Trap combined with docetaxel is 
currently under investigation in a phase I/II trial of patients 
with persistent or recurrent EOC, PPC, or fallopian tube 
cancer (NCT00436501).
Small molecule receptor tyrosine kinase inhibitors (TKIs) 
targeting the VEGF pathway are also being examined. 
Cediranib, a competitive inhibitor of VEGFR2, is currently 
under investigation in the ICON 6 trial. In this   randomized, 
phase III trial, cediranib with carboplatin/paclitaxel 
chemotherapy is being compared to carboplatin/paclitaxel 
alone in a sample of women with recurrent, mostly platinum-
sensitive, EOC utilizing overall survival as the primary end 
point.87 Vandetanib is another TKI which interferes with 
both VEGFR2 and EGFR, resulting in its antiangiogenesis 
and antiproliferative activity. Combination regimens with 
vandetanib and liposomal doxorubicin (NCT00862836) and 
docetaxel (NCT 00872989) are currently under investigation 
in phase I and/or II trials.
EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3, and ErbB4 
are 4 tyrosine kinase receptors which comprise the EGFR 
receptor family.88 Following ligand binding, these receptors 
undergo dimerization, internalization of the ligand-receptor 
complex, and finally tyrosine auto-phosphorylation.85 Via 
downstream targets such as PI3K/Akt and MAPK, activation 
of EGFR receptors ultimately leads to cellular proliferation, 
differentiation, metastasis, and angiogenesis.89 As a result, 
monoclonal antibodies have been created to inhibit these 
EGFR-dependent pathways, most notably EGFR and ErbB2 
(HER2). Cetuximab and panitumumab are mouse/human chi-
meric and human monoclonal antibodies, respectively, which 
target EGFR. Trastuzumab and pertuzumab are monoclonal 
antibodies which target ErbB2/HER2.
In a phase II trial, cetuximab monotherapy was adminis-
tered to 25 women with persistent or recurrent EOC or PPC 
(64% with platinum-resistant disease) in order to determine 
its safety and efficacy.90 Only 1 patient (4%) with platinum-
resistant EOC experienced an objective partial response; 
this trial was subsequently terminated due to poor response 
rate. While all patient tumors expressed EGFR, the authors 
postulated that future investigation should focus on deter-
mining which subcohort of patients would directly benefit 
from therapy. Panitumumab is a monoclonal antibody which 
has been studied in EGFR-expressing metastatic colorectal 
cancer.91 Panitumumab in combination with PLD is currently 
under investigation in a phase II trial with platinum-resistant, 
KRAS wild-type EOC patients (NCT00861120).
After demonstrating the ability to prolong disease-free 
and overall survival in breast cancer, trastuzamab, a mono-
clonal antibody that interferes with the HER2 receptor, has 
been approved for use as an adjuvant therapy in patients 
with HER2-positive breast cancer.92 HER2 expression is 
negatively correlated to survival in ovarian cancer patients.93 
In a phase II GOG trial, trastuzumab was administered as 
a single agent to 41 women with HER2-positive, recurrent, 
or persistent EOC or PPC.94 There was an overall response 
rate of 7.3% with a median progression-free survival of Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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2.0 months, suggesting that the overall potential therapeutic 
benefit for trastuzamab in EOC may be limited.
Pertuzumab, a monoclonal antibody referred to as a 
“HER dimerization inhibitor”, is currently being evaluated in 
patients with HER2-positive EOC due to the ability to prevent 
activation of HER2 downstream pathways.85 In a randomized 
controlled phase II trial of 130 women with platinum-resistant 
EOC/fallopian tube cancer/PPC, women who had received 
pertuzumab and gemcitabine had better ORRs (13.8% vs 
4.6% for placebo group) and a trend towards improved 
progression-free survival (hazard ratio 0.66, P = 0.07) when 
compared to a sample receiving gemcitabine and placebo.95 
While these findings were nonsignificant, the authors suggest 
that with further study pertuzumab may be an effective agent 
for the treatment of platinum-resistant disease.
TKIs targeting the EGFR family, including gefitinib 
and erlotinib, are currently under evaluation. In a phase 
II GOG trial, gefitinib was administered to a group of 27 
women with recurrent or persistent EOC or PPC, consist-
ing of 37% and 63% with platinum-sensitive and -resistant 
disease, respectively.96 Only 1 patient (4%) experienced an 
objective response to treatment; however, women in this 
trial were not prescreened for EGFR mutations which the 
authors argue may improve response rates to gefitinib. These 
results were further substantiated in a phase II trial in which 
there were no objective responses to gefitinib monotherapy 
in women with heavily pretreated, recurrent EOC who had 
detectable levels of EGFR (both total and a phosphorylated 
form).97 In a recent phase II trial, erlotinib and carboplatin 
combination therapy was more active in sensitive than 
-  resistant disease.98 Trials combining erlotinib with topotecan 
(NCT01003938) and with bevacizumab (NCT00126542, 
NCT00696670) are currently under way.
In addition to EGFR, investigations have focused on 
other growth factor receptors critical to the angiogenesis 
pathway. Platelet-derived growth factor receptor (PDGFR), 
a tyrosine kinase receptor which enhances cellular prolifera-
tion, is present in 50% to 80% of ovarian cancers.99 TKIs 
targeting PDGFR, including imatinib, sorafenib, sunitinib, 
and pazopanib, are presently under review in recurrent 
EOC. Imatinib, a TKI with activity against Abl, PDGFR, 
and c-kit, has minimal activity in platinum-resistant disease, 
as highlighted by 2 recent phase II trials.100,101 Sorafenib, 
which targets VEGFR, PDGFR, and c-kit, is currently being 
examined in combination with topotecan (NCT01047891) 
and gemcitabine (NCT00096395). Treatment with sunitinib, 
which targets VEGFR and PDGFR, produced no objective 
responses in a phase II trial of women with recurrent ovarian 
cancer.102 Pazopanib, a TKI targeting VEGFR, PDGFR, and 
c-kit, has produced an ORR of 18% in a phase II trial with 36 
recurrent EOC patients, including 9 with platinum-refractory 
and -resistant disease.103 In addition to small molecule TKIs, 
a monoclonal antibody, IMC 3G3, has been introduced which 
inhibits the PDGFRα; this antibody combined with PLD is 
currently under review in a phase II trial of platinum-resistant 
EOC patients (NCT00913835).
Aurora kinases and members of the hedgehog and PI3K/
AKT/mTOR signaling pathways have also been examined 
as novel targets for recurrent EOC therapy; the results of 
several phase II trials involving these agents are currently 
pending.
Folate metabolism
Folate receptor-alpha (FRα) is a glycosyl-phosphatidylinos-
itol-linked member of the folate receptor family which is 
overexpressed in the majority of nonmucinous EOCs.104,105 
FRα binds folic acid with high affinity, permitting cancer 
cells to grow in low folate concentrations and thereby facili-
tating DNA synthesis.106 Three anti-human FRα monoclonal 
antibodies have been studied in clinical trials: MOV18, 
murine LK26 and MORAb-003. MOV18 is a murine or 
chimeric anti-FR monoclonal antibody which had been 
administered to women with ovarian cancer in phase I trials 
and suggested a clinical benefit with minimal toxicity.107,108 
More recently, this antibody has been investigated in radio-
immunotherapy preclinical studies.109,110 LK26 is another 
murine anti-FR antibody which had been investigated in 
preclinical trials but was never studied in clinical trials due 
to its decreased affinity for the FR following humanization 
of the antibody.111 MORAb-003, a humanized anti-FR mono-
clonal antibody, was subsequently derived by optimizing the 
LK26 molecule. MORAb-003 has been studied in phase I and 
II trials;112,113 preliminary results suggest that this molecule 
is safe and efficacious in the treatment of EOC. The utility 
of this molecule in treating platinum-resistant disease will 
hopefully be determined by a randomized, double-blinded, 
placebo-control study examining paclitaxel with and without 
concurrent MORAb-003 (NCT00738699).
Cellular adhesion
Cellular adhesion molecules, including epithelial cell-
  adhesion molecule (EpCAM), mesothelin, and integrin, 
may play critical roles in tumor metastasis and are cur-
rently molecular targets in recurrent EOC. EpCAM is an 
antigen expressed in the majority of epithelial cancers,114 
and is   significantly overexpressed in recurrent EOC when Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  compared with normal ovarian tissue and with primary 
ovarian   carcinomas.115 Further, EpCAM is highly expressed 
on the surface of chemotherapy-resistant ovarian cancer 
cell lines.115 EpCAM is thus a molecule which can facilitate 
targeted immunotherapy in the local tumor microenviron-
ment, especially for those women with recurrent and che-
motherapy resistant disease. Catumaxomab is a trifunctional 
antibody with 2 antigen-binding sites, targeting EpCAM on 
epithelial tumor cells and CD3 on T cells, with a functional 
Fc domain.116 Thus, this antibody functions to recruit and 
activate immune effector cells at the tumor site. In a random-
ized, 2-arm phase II/III trial, IP catumaxomab in combination 
with paracentesis was compared with paracentesis alone in 
258 patients with recurrent, symptomatic malignant ascites, 
including 129 patients with primary ovarian cancer.117 In the 
ovarian cancer patients, median puncture-free survival and 
time to next paracentesis were both significantly prolonged in 
the combination group compared with the paracentesis alone 
group, suggesting that catumaxomab provides a clinical ben-
efit to those women with EOC-related malignant ascites.
Mesothelin is overexpressed on ovarian cancer cell mem-
branes and is believed to be involved in cellular adhesion.118 
An anti-mesothelin immunotoxin, SS1P, has recently been 
examined in phase I trials of mesothelin-expressing tumors 
and while clinical activity has been suggested, these findings 
need to be further confirmed.118 Integrins are receptors that 
are important in cellular adhesion; a monoclonal antibody 
to alpha(v)-integrins is currently under investigation in 
phase I trials.
Hormonal therapy
Hormones, particularly estrogen and progesterone, play key 
roles in ovarian carcinogenesis. This association is probably 
best highlighted by the fact that oral contraceptive pill use 
decreases the incidence of ovarian cancer.119 Further, estro-
gen and progesterone receptors are often present on ovarian 
cancer cells, and in vitro responses have been reported to 
tamoxifen and other hormonal agents.120 Unlike in breast 
cancer, hormone-driven therapy has not been met with suc-
cess in the treatment of platinum-resistant EOC.
Selective estrogen receptor modulators, specifically 
tamoxifen, have been investigated in the treatment of 
  platinum-resistant disease. In a recent Cochrane review, 
the role of tamoxifen in recurrent EOC could not be estab-
lished due to a lack of comparative studies.121 However, 
when analyzing noncomparative studies, an overall ORR 
of 9.6% was determined, with individual studies reporting 
ranges from 0% to 56%. Aromatase inhibitors inhibit the 
  conversion of androgens into estrogens via the aromatase 
enzyme. These agents, particularly letrozole, have also been 
studied in the treatment of platinum-resistant EOC. In a 
single-  institution, phase II trial, letrozole produced an ORR 
of 3% in a sample of patients with platinum- and taxane-
resistant, estrogen-receptor positive recurrent EOC or PPC 
and 74% of patients experienced disease progression.122 Fur-
thermore, an ORR of 9% was appreciated in a sample of 42 
women with estrogen-positive relapsed EOC, of which 43% 
of individuals had platinum-resistant disease.123 Fulvestrant 
is a novel estrogen receptor antagonist which does not pos-
sess any agonistic effects. In a single-institution, phase II 
trial, fulvestrant produced no objective responses by modi-
fied RECIST criteria in a sample of 26 heavily pretreated 
EOC patients but did stabilize disease in 35% of patients.124 
No further studies are currently available which focus on 
the use of this agent specifically in platinum-resistant dis-
ease. Mifepristone is a competitive progesterone receptor 
antagonist which has recently been studied in platinum-
resistant EOC. In a phase II GOG trial, mifepristone was 
administered to patients with recurrent or persistent EOC, 
fallopian tube cancer, or PPC.125 While it is unclear how 
many patients had platinum-resistant disease, only 1 patient 
experienced an objective response, suggesting that this agent 
is likely not effective in this patient sample. No additional 
studies have been reported. GnRH analogs have also been 
investigated in platinum-resistant EOC. In a sample of 12 
patients with platinum-resistant disease, leuprolide produced 
an ORR of 8.3%; however, 66.7% patients experienced 
disease   progression.126 In a nonrandomized, phase II trial, 
goserelin in combination with tamoxifen was administered 
to 26 patients with recurrent EOC, including 65% with 
platinum-resistant disease.127 While authors suggest that 50% 
of patients experienced a clinical benefit, objective responses 
were experienced in only 3 patients (11.5%). A luteinizing 
hormone-releasing hormone antagonist, cetrorelix, has also 
been shown to modest activity in a cohort of patients with 
platinum-resistant disease.128
DNA repair pathways
BRCA 1 and 2 are two proteins that play critical roles in 
homologous recombination, a process that repairs double-
stranded DNA breaks.129 Germline mutations in BRCA 1 
and 2 are present in up to 15% of women afflicted with 
ovarian cancer.130 Inhibition of an additional DNA repair 
pathway, specifically base excision repair (BER), has been 
shown to be a lethal event in BRCA dysfunctional cells, 
a term commonly referred to as synthetic lethality.131 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Poly-ADP-ribose polymerase (PARP) is a nuclear enzyme 
which participates in BER and has been a current target 
of therapy in BRCA dysfunctional patients. While initial 
investigation has focused on the use of PARP inhibitors in 
individuals with germline mutations, a recent report sug-
gests that additional EOC patients with somatic BRCA 1 
or 2 dysfunction, a phenotype referred to as “BRCAness”, 
may also benefit from this novel drug class.132 Olaparib 
is the most studied PARP inhibitor in women with EOC. 
In a multicenter, international phase II trial, 100 mg and 
400 mg doses of olaparib were administered to women 
with BRCA 1 or 2 germline mutations who had recurrent 
EOC, fallopian tube cancer, or PPC;133 the trial included 
women with both platinum-sensitive and -resistant disease. 
ORRs were appreciated in 33% of patients receiving the 
400 mg twice daily dose and 13% of patients receiving the 
100 mg twice daily dose. Further, women with platinum-
sensitive and -resistant disease experienced ORRs of 38% 
and 30%, respectively, with the 400 mg dosing regimen. 
These encouraging results suggest that olaparib may be an 
efficacious and safe treatment option in BRCA-mutated 
advanced ovarian cancer.
Other PARP inhibitors, including veliparib, iniparib 
(BSI 201), and AG014699, are currently under investiga-
tion as monotherapy or in combination with other chemo-
therapeutic agents in women with recurrent ovarian cancer. 
Veliparib in combination with pegylated liposomal doxo-
rubicin is being studied in a phase I trial of women with 
recurrent EOC, fallopian tube cancer, PPC, or metastatic 
breast cancer (NCT01145430). Iniparib in combination 
with carboplatin and gemcitabine is currently being studied 
in resistant ovarian cancer patients (NCT01033292). The 
results of these studies will certainly help to determine the 
role of PARP inhibitors in the treatment of recurrent ovarian 
cancers, including those with BRCA germline and somatic 
dysfunction.
Conclusion
Current available treatments for platinum-resistant ovarian 
cancer generally produce modest response rates approach-
ing 20%, which indicates significant room for improve-
ment. In addition to novel cytotoxic agents, emerging 
approaches based on small molecules and biologics now 
focus on targets critical to ovarian carcinogenesis, metas-
tasis, and immune surveillance. A number of these targets 
have been examined in phase I and II clinical trials with 
encouraging results, and while early data are limited, 
further investigation with single-agent or combination 
therapies may offer new hope to women with this lethal 
disease.
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